Kymera Therapeutics, Inc. Common Stock

KYMR · Biotechnology · $9.8B

Cooling off

KYMR

$117.75

▼ −0.62%

09/18 O 119.06 H 119.06 L 116.36 C 117.75 ▼ −0.62%
Vol 1.9M RS 93

RS rating93

Now vs pivot (%)−9.46%

Tightening (ATR ratio)1.40×

Volume dry-up1.23×

Up/down volume, net0.04

From 52-week high9%

forming

Previous breakout trailed out ▲ +13.78% in Jun

Moving averages

9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 12.0 weeks and fell 23% from its ceiling at its deepest. The pivot is $130.05, and the stock closed 9.5% below it. Its relative strength rating is 93.

Also on

vcp · forming blue sky · forming

Peers

Same industry

MRNA99 TWST99 IOVA98 AGEN97 CGEM97 INBX97 RLAY97 RVMD97

Same theme

No themes — common and fine.

Catalyst roadmap

Earningstentativein 46d
Quarterly earnings
Nov 3, 2026
Add to calendar

Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news

No headlines for this company in the last couple of weeks.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray